Analysts See $0.41 EPS for Health Insurance Innovations, Inc. (HIIQ); Last Week Smith & Nephew plc (LON:SN) Analysts

April 24, 2018 - By Winifred Garcia

Smith & Nephew plc (LON:SN) Logo

Among 20 analysts covering Smith Nephew PLC (LON:SN), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Smith Nephew PLC had 213 analyst reports since July 23, 2015 according to SRatingsIntel. Barclays Capital maintained it with “Overweight” rating and GBX 1250 target in Wednesday, November 25 report. Barclays Capital maintained Smith & Nephew plc (LON:SN) on Wednesday, August 26 with “Overweight” rating. Deutsche Bank maintained Smith & Nephew plc (LON:SN) on Monday, August 1 with “Hold” rating. The stock of Smith & Nephew plc (LON:SN) earned “Hold” rating by Jefferies on Tuesday, April 12. Deutsche Bank maintained the stock with “Buy” rating in Friday, October 13 report. The stock has “Add” rating by AlphaValue on Wednesday, August 19. Credit Suisse maintained the shares of SN in report on Friday, May 6 with “Neutral” rating. The firm has “Buy” rating by Deutsche Bank given on Monday, October 12. On Friday, February 5 the stock rating was maintained by Deutsche Bank with “Hold”. The rating was maintained by Goldman Sachs with “Buy” on Friday, February 5. See Smith & Nephew plc (LON:SN) latest ratings:

17/04/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 1315.00 New Target: GBX 1309.50 Maintain
12/04/2018 Broker: Jefferies Rating: Buy Old Target: GBX 1515.00 Maintain
05/04/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 1411.00 New Target: GBX 1463.00 Maintain
26/03/2018 Broker: HSBC Rating: Buy Old Target: GBX 1320.00 New Target: GBX 1530.00 Upgrade
13/02/2018 Broker: Morgan Stanley Rating: Equal Weight Old Target: GBX 1558.00 New Target: GBX 1457.00 Maintain
09/02/2018 Broker: Credit Suisse Rating: Neutral Old Target: GBX 1285.00 New Target: GBX 1290.00 Reiteration
07/02/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 1411.00 New Target: GBX 1411.00 Maintain
01/02/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 1411.00 New Target: GBX 1411.00 Maintain
25/01/2018 Broker: JP Morgan Rating: Overweight Old Target: GBX 1369.00 New Target: GBX 1411.00 Upgrade
13/11/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 1382.00 New Target: GBX 1369.00 Maintain

Analysts expect Health Insurance Innovations, Inc. (NASDAQ:HIIQ) to report $0.41 EPS on May, 2.They anticipate $0.05 EPS change or 13.89% from last quarter’s $0.36 EPS. HIIQ’s profit would be $6.80 million giving it 17.04 P/E if the $0.41 EPS is correct. After having $0.26 EPS previously, Health Insurance Innovations, Inc.’s analysts see 57.69% EPS growth. The stock decreased 1.76% or $0.5 during the last trading session, reaching $27.95. About 146,615 shares traded. Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has risen 102.80% since April 24, 2017 and is uptrending. It has outperformed by 91.25% the S&P500.

Since December 18, 2017, it had 0 insider purchases, and 6 selling transactions for $3.80 million activity. 5,000 shares valued at $141,500 were sold by Wang Sheldon on Thursday, January 25. Another trade for 9,970 shares valued at $360,799 was made by Telkamp Bruce on Thursday, March 29.

Health Insurance Innovations, Inc. operates as a developer, distributor, and administrator of cloud individual health and family insurance plans, and supplemental products in the United States. The company has market cap of $463.23 million. The firm offers short-term medical plans that cover individuals for up to 364 days with various deductible and copay levels; hospital indemnity plans, which provide daily cash benefit for hospital treatment and doctor office visits, as well as accidental injury and death or dismemberment benefits; and supplemental insurance products comprising pharmacy benefit cards, dental plans, vision plans, and cancer/critical illness plans, as well as deductible and gap protection plans, and life insurance policies. It has a 18.63 P/E ratio. It creates and structures individual health and family insurance plans, and supplemental products on behalf of insurance carriers and discount benefit providers; and market them to individuals through a network of distributors.

Among 8 analysts covering Health Insurance Innovations Inc (NASDAQ:HIIQ), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Health Insurance Innovations Inc had 39 analyst reports since August 13, 2015 according to SRatingsIntel. Canaccord Genuity maintained the shares of HIIQ in report on Thursday, February 15 with “Buy” rating. The rating was maintained by Canaccord Genuity with “Buy” on Friday, January 26. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has “Buy” rating given on Thursday, September 15 by Lake Street. As per Tuesday, September 5, the company rating was maintained by Northland Capital. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, April 12. The company was maintained on Monday, October 16 by Cantor Fitzgerald. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has “Buy” rating given on Thursday, December 21 by Canaccord Genuity. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) earned “Buy” rating by Canaccord Genuity on Friday, July 28. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has “Buy” rating given on Friday, September 1 by Cantor Fitzgerald. The stock of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has “Buy” rating given on Wednesday, November 1 by Cantor Fitzgerald.

Investors sentiment decreased to 0.95 in 2017 Q4. Its down 0.78, from 1.73 in 2017Q3. It turned negative, as 31 investors sold Health Insurance Innovations, Inc. shares while 27 reduced holdings. 20 funds opened positions while 35 raised stakes. 10.59 million shares or 5.28% more from 10.06 million shares in 2017Q3 were reported. Sg Americas Securities Ltd Liability Corp invested in 0% or 9,522 shares. Vanguard Grp Incorporated owns 630,142 shares or 0% of their US portfolio. New York-based Prelude Cap Ltd Liability Corporation has invested 0.32% in Health Insurance Innovations, Inc. (NASDAQ:HIIQ). Citigroup Incorporated holds 0% or 187 shares in its portfolio. Arrowstreet Capital Ltd Partnership holds 0.04% or 668,208 shares. Mackenzie Financial stated it has 21,768 shares. Millennium Management Lc owns 0.01% invested in Health Insurance Innovations, Inc. (NASDAQ:HIIQ) for 340,728 shares. Caprock Grp Inc owns 40,000 shares. Bowling Mgmt Limited Liability Co owns 104,537 shares or 0.35% of their US portfolio. New York-based Oz L P has invested 0% in Health Insurance Innovations, Inc. (NASDAQ:HIIQ). Moreover, Prudential Pcl has 0.02% invested in Health Insurance Innovations, Inc. (NASDAQ:HIIQ). Credit Suisse Ag reported 37,815 shares or 0% of all its holdings. Barclays Public Ltd Liability Corporation owns 6,438 shares. Meeder Asset Management Inc owns 0% invested in Health Insurance Innovations, Inc. (NASDAQ:HIIQ) for 478 shares. Bridgeway Capital Mgmt has 0.02% invested in Health Insurance Innovations, Inc. (NASDAQ:HIIQ).

Since January 3, 2018, it had 0 insider purchases, and 13 sales for $1.02 million activity. 19,903 shares valued at $103,894 were sold by Heinson Christopher on Monday, January 8. The insider Kopel Gregory B sold $12,300. 19,618 shares were sold by SANCHEZ ANTONIO R JR, worth $58,481 on Thursday, March 1. 9,949 shares valued at $51,934 were sold by Hink Kirsten A on Monday, January 8. Shares for $49,059 were sold by Sanchez Patricio D.. Another trade for 8,251 shares valued at $24,596 was made by Thill Howard J SR on Thursday, March 1.

The stock decreased 0.29% or GBX 4 during the last trading session, reaching GBX 1385. About 655,466 shares traded. Smith & Nephew plc (LON:SN) has 0.00% since April 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Health Insurance Innovations, Inc. (NASDAQ:HIIQ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>